A new polyacetal polysulphatevtermed PAPS, was synthesized starting from dextranthrouqh oxidation, reduction, and subsequent sulphation. PAPS inhibited· HIV-1-and HIV-2-induced cytopathicity in MT-4 cells at concentrations comparable to those required for dextran sulphate (MW 5000) to inhibitthe cytopathicity of these viruses (50% inhibitory concentration: 0.4-O.04/Lg ml"), At these concentrations PAPS had no anticoagulant activity. PAPS suppressed syncytium formation between MOLT-4 cells and persistently HIV-1-or HIV-2-infected HUT-78 cells at a concentration of 1/Lg mr ', that is 25-to 30-fold lower than that required for dextran sulphate to inhibit syncytium formation. Like dextran sulphate, PAPS inhibitedHIV-1 binding to the cells and anti-gp120 mAb binding to HIV-1 gp120. Also, PAPS proved equally active as dextran sulphate against herpes simplex virus, cytomegalovirus and the areilaviruses Junin and Tacaribe, and 10-fold more active than~extran sulphate against vaccinia, Sindbis, influenza A, and vesicular stomatitis virus. Neither PAPS nor dextran sulphate proved inhibitory to the non-enveloped viruses polio, Coxsackie and reovirus. Pharmacokinetic studies in rabbits revealed that after intravenous bolus injection the serum concentrations of PAPS decayed biphasically, witli an initial half-life of approximately 45-60 min. Twenty-four hoursfollowing their intraperitoneal administration to mice, PAPS as well as dextran sulphate generated low titres of an antiviral principle that was at least partially interferonlike.
ntroduction
Sulphated polysaccharides, such as heparin, dextran sulphate, lentinan sulphate, mannan sulphate, pentosan polysulphate, fucoidan, dextrin sulphate and sulphated cyclodextrins are potent inhibitors of the replication of human immunodeficiency virus (HIV) in vitro (Ito et al., 1987 (Ito et al., , 1989 (Ito et al., , 1991 Ueno and Kuno, 1987; Saba et al., 1988a,b; Mitsuya et al., 1988; De Clercq, 1989 , 1991 Hatanaka et aI., 1989; Tochikura et aI., 1989; Anand et al. 1990; McClure et al., 1991; Moriya et aI., 1991; Schols et al., 1991; Witvrouw et al., 1991) . A sugar backbone is not strictly needed for antiviral activity, since sulphated polymers, such as polyvinylalcohol sulphate (PVAS) and its co-polymer with acrylic acid (PAVAS), have also proved to be efficient anti-HIV agents in vitro (Saba et aI., 1990a; Schols et al., 1990a) .Their mechanism of action has been attributed to an inhibition of virus adsorption to the cell membrane (Saba et al., 1988a (Saba et al., , 1988b (Saba et al., , 1988c (Saba et al., , 1990a (Saba et al., , 1990c Mitsuya et al., 1988; Nakashima et aI., 1989; Schols et al., 1989a) . Sulphated polysaccharides, and polysulphates in general, are not only inhibitory to HIV but also to other enveloped viruses including herpes simplex, cytomegalo, vesicular stomatitis, respiratory syncytial virus and various toga-, arena-, and retroviruses (Saba et al., 1988c; Schols et al., 1990a) .
We have now synthesized a new polysulphate based on a polyacetyl backbone. The compound was termed PAPS. It proved inhibitory to a wide range of enveloped DNA and RNA viruses including HIV-1 and HIV-2 at concentrations well below the anticoagulant threshold. The anti-HIV activity of PAPS, like that of dextran sulphate, can be attributed to inhibition of the viral adsorption process. Like dextran sulphate, PAPSspecifically interacts with the viral gp120 glycoprotein. PAPS inhibits syncytium formation between HIV-infected and uninfected cells at a much lower concentration than dextran sulphate. It also generates an interferon-like activity in the serum when administered intraperitoneally to mice. Following intravenous administration to rabbits, substantial serum levels of PAPS could be detected by an anti-HIV-2 bioassay specifically developed for this purpose.
Results

Anti-HIVactivity
When PAPS [prepared from dextran (MW 19500) ] was I PAPS achieved 50% reduction in syncytium (giant cell) formation (induced by either HIV-1 or HIV-2) at a concentration of 1 I-'-g mr', In this regard, PAPS was much more effective than dextran SUlphate which effected 50% reduction in giant cell formation only at a concentration of 25-30l-'-g mr' (fable 1).
Mechanism of anti-HIV activity
Using a flow cytometric method (Schols et al., 1989a) , we have previously demonstrated that dextran sulphate blocks HIV-1 binding to the cells. Using the same procedure, we found that PAPS achieves an equally strong inhibition of HIV-1 binding to MT-4 cells as dextran sulphate (both tested at 251-'-g mr') ( Fig. 1 ).
Dextran sulphate has been shown previously to directly interact with the HIV envelope glycoprotein gp120 (Schols et aI., 1990b) . The viral gp120 is involved in both virus-cell binding and giant cell formation (Skinner et al., 1988) . PAPS and dextran sulphate were examined for their ability to interfere with the binding of anti-gp120 mAb (recognizing the V3 region of gp120) to persistently HIV-1 infected HUT-78 cells. As shown in Table 2 , both compounds exerted a comparable inhibitory effect on the binding of the anti-gp120 mAb, even if the compounds had been exposed to the cells for only 15 min at room temperature. c I I ' • '} 10 I 10 2 IOR elative Green Fluorescence Fig. 1 . Inhibitory effect of PAPS and dextran sulphate on HIV-1 binding to MT-4 cells. The fluorescence of MT-4 cells that were not exposed to HIV-1 is presented by the white histogram and fluorescence of MT-4 cells which were exposed to HIV is presented by the dark histogram. The MT-4 cells were exposed or not exposed to HIV-1 in the absence of any compound (A), in the presence of dextran sulphate at 25 fLg mr' (B) or in the presence of PAPS at 25 fL9 mr' (C). inhibitory concentration (IG so ) was 0.4 I-'-g rnr ". PAPS was 1O-fold more inhibitory to HIV-2(LAV-2 RoD)-induced cytopathicity, where its IG so was 0.04 I-'-g mr" . When tested in parallel with PAPS, dextran sulphate (MW 5000) gave comparable IG so values (fable 1). Neither PAPS .nor dextran sulphate reduced the viability of mock-infected MT-4 cells, as measured by both trypan blue exclusion and the MTT method (Pauwels et et., 1988) , at concentrations up to 2.5mg rnr' (fable 1).
Activity against DNA and RNA viruses other than HIV
When PAPS was examined for its inhibitory effect on the replication of DNA viruses, it proved markedly inhibitory to HSV-1, HSV-2, TK-HSV-1 and, in particular, GMV (fable 3). The IG so of PAPS for HSV-1, GMV and W was 3-to 10-fold lower than the IG so of dextran sulphate. When PAPSwas examined for its inhibitory effect on the replication of RNA Virusesother than HIV-1 or HIV-2 (fable 3), the compound was found to be active against Sindbis virus, influenza virus A, RSV,and VSV at a 5-to 10-fold lower IG so than the IG so of dextran sulphate. The IG so of PAPSfor Junin and Tacaribe virus was comparable to that of dextran sulphate. Neither PAPS nor dextran sulphate 
HIV-1-infected HUT-78 cells (200000/1 00 p.l of RPM I with 10% FCS) were washed twice, incubated with the compounds at the indicated concentrations at 20°C for 15 min, stained, and analysed as described in the Materials and Experimental procedures section. The inhibitory index for anti-gp120 mAb binding inhibition (H9p120) was calculated according to the following formula: IIgp120 = 1 -(MFgP12ox -MFc)/(MFgP120-MFc), where MFgP120 is the mean channel fluorescence (MF) for the cells incubated only with anti-gp120 mAb, MFgp120x is the MF for the cells incubated with test compound and anti-gp120 mAb, and MFc is the mean channel fluorescence of the cells incubated only with RaM-lgG-F(ab')2-FITC. Mean channel fluorescence was determined by the Consort 30 program (Becton-Dickinson 
o with both PAPS and dextran sulphate at doses of 120mg kg-1 (Fig. 3 ). No IFN activity was detected in serum samples from control mice.
Experiments were then performed to determine the nature of the antiviral principle found in the serum. Serum samples from mice treated with PAPS or dextran sulphate were incubated with polyclonal goat anti-mouse alf3 IFN antibodies for 4h at 3JOC. Residual IFN titres were then assayed in L-929 cells with VSV as challenge virus. The antiviral activity of the serum samples from mice that received a PAPS dose of 120 mg kg-1 , decreased from 62 IU mr' to 30 IU rnl" following incubation with anti-mouse a/f3 IFN antibody. This means that part of the antiviral activity generated by PAPS may be of the IFN a/f3 type.
Discussion
Our studies have indicated that PAPS, like sulphated polysaccharides (Le.dextran sulphate) (Saba et el., 1988c) and sulphated polymers (l.e. polyvinylalcohol sulphate) , has a broad-spectrum antiviral activity against a variety of enveloped viruses. PAPS is particularly active against HIV and CMV. It inhibits the (Table   1) ], neither PAPS nor dextran sulphate caused prolongation of the APTI.
Pharmacokinetics of PAPS in rabbits
When PAPS was administered intravenously to rabbits at a dose of 0.1 9 kg-1 , the compound concentration in the serum at 20 min after injection was 1.2 mg mr' (Fig. 2) , as compared to 0.5mg mr' for dextran sulphate when evaluated under similar conditions (Witvrouw et el., 1990) . At 8h after injection, the concentrations of PAPS in the serum was 40 J.Lg mr'. The serum concentration of PAPS declined biphasically with an initial half-life of approximately 45-60 min. (Reichert et al., 1983 ). An interesting feature of PAPS, which it shares with dextran sulphate, is its ability to induce, albeit low-titred, interferon-like activity in the serum of mice. This confirms previous data on IFN induction by polysulphates (Came et aI., 1969) . Polyanionic substances such as polycarboxylates and polysulphates have since long been known for their capacity to elicit a so-called late mterteron response, peaking at about 24 h (DeClercq, 1974; ; oSinee et aI., 1990) . Through their ability to induce interferon, and possibly other cyto-or Iymphokines, PAPS and other polysulphates may have an immunorestorative effect in the host. This would then contrast with other antiviral drugs, such as azidothymidine (AZT), which rather act as immunosuppressive agents upon prolonged use (Yarchoan et al., 1986) .
Another interesting feature of PAPS is its ability to block HIV-1-and HIV-2-induced syncytium formation at a concentration (1 fL9 ml-1 ) which is significantly lower than the concentration (25-30 fL9 rnr") at which dextran sulphate inhibits syncytium formation (Witvrouw et al., 1991) and comparable to the concentration at which PVAS and PAVAS inhibit syncytium formation . Azidothymidine and other dideoxynucleoside analogues do not block syncytium formation (Mitsuya et al., 1988) . Syncytium formation may play an important role in the pathogenesis of AIDS (Haseltine, 1988) , since it. could possibly account for the depletion of CD4+ cells in AIDS patients (Schols et al., 1989b) .
The mechanism of anti-HIV action of PAPS may be attributed to the inhibition of virus binding to the cells (Fig.  1) , which, in turn, appears to be mediated by the direct interaction of the compound with the viral envelope glycoprotein (gp120) ( Table 2 ). The broad antiviral activity spectrum of PAPS, encompassing, in addition to HIV, other enveloped RNA and DNA viruses (such as VSV, HSV and CMV), may also be based on the inhibition of virus binding to the host cells.
PAPS is markedly more effective than dextran sulphate in a number of assay systems: HIV-1-and HIV-2-induced giant cell formation (Table 1) , VSV-, HSV-1, and CMV-New polyacetal polysulphate 355 induced cytopathicity (Table 3) . Also, higher serum concentrations are achieved with PAPS (Fig. 2 ) than with dextran sulphate (Witvrouw et al., 1990) ,following intravenous bolus injection of the compounds to rabbits. Therefore, PAPS may be at least as good, if not a better candidate drug than dextran sulphate, to be further pursued for the therapy and prophylaxis of HIV, CMV, and other virus infections.
Materials and Experimental procedures
Compounds
Dextran sulphate (MW 5000) and dextran (MW 19500) were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Polyacetal polysulphate (PAPS) (Fig. 4) is a polymer containing several types of structural units, all linked to each other via acetal groups. PAPS consists for a major part of repeating units with two alcohol functions which are partly sulphated, and for a minor part of partly sulphated 1,6-linked anhydropyranose units and some dialdehyde units. The PAPS preparation used was obtained from dextran in three steps. In the first oxidation step (Claes et al., 1970) , the anhydropyranose units of dextran were cleaved by reaction with sodium meta-periodate, thus affording the polyaldehyde oxydextran A. The aldehyde functions of the latter were reduced to alcohol functions by reaction with sodium borohydride (Nevell, 1963) to afford compound B, which was subsequently sulphated with the pyridine-sulphur trioxide complex (Whistler et al., 1963) , to yield PAPS (Fig. 4) .
A solution of dextran (1 Og)(MW 19500, Sigma Chemical Co.) in 0.2 M sodium meta-periodate (740ml), buffered at pH 3.6 (Hough, 1965) , was stirred in the dark at 5°C under a nitrogen atmosphere. After 24h, the total periodate consumption (Jackson, 1944) had reached a constant value, and ethylene glycol (2ml) was added. After an additional 24h at 5°C, mineral salts were removed by dialysis (Visking dialysis tubing 10000 Dalton) against distilled water at 5°C. The dialyzed solutions were concentrated under reduced pressure below 30°C. Addition of 2.5 volumes of t-butyl alcohol yielded gummy precipitates which were triturated with absolute ethyl alcohol and dried in vacuo (yield: 7 g).The degree of oxidation was determined using the known hydroxylamine method (Green, 1963) , and was calculated to be 86.4%, expressed as the mole fraction of the oxidized anhydropyranose units, on a dry basis.
This oxydextran A (6.2g) was then solubilized in 310ml of 1M sodium borohydride solution, which was stirred at room temperature for 24h. The solution was dialyzed against distilled H 2 0 at room temperature until its pH was about 7. The volume was then reduced to 50ml by evaporation at reduced pressure, and the remaining water was removed by Iyophylization. The resulting solid was triturated with dry MeOH, and dried over P20 S in vacuo (6.4g, 60.4% yield). Hydroxylamine analysis revealed the aldehyde content to be 8.2% (on a dry basis).
In the third step, 1.95 g of compound B was dissolved in 50 ml of dry DMF. Pyridine-sulphur trioxide complex (6.03g) was added, and the mixture was reacted for 3h at 50°C and for an additional 17h at room temperature. The solvent was removed under reduced pressure and 350ml of a saturated sodium bicarbonate solution was added to the residue. The solvent was again 62.2% sUlphatation of the hydroxyl groups evaporated, and the residue was solubilized in 200 ml water. This solution was dialyzed against distilled water until a neutral pH was reached. Further work-up was similar to that for compound Band 3.4g of PAPS (sodium salt) were obtained. We calculated the molecular weight of this preparation to be approximately 31600 Daltons, as we do not expect any chain degradation, based on previous experience with the sulphatation of cyclodextrins (Schols et a/., 1991) .
Determination of the degree of sulpnetetkm
The degree of sulphatation (percentage of hydroxyl groups sulphated in PAPS)was determined by titration of the compound after passage through an AG50W-X8 column in the H+ form. The free acid was titrated with 0.2 N NaOH and the degree of sulphatation, calculated from these results, amounted to 62.2% on a dry basis.
Cells
MT-4 cells (Miyoshi et a/., 1982) and MOLT-4 cells (clone 8) (Kikukawa et aI., 1986) 
Viruses
The virus stocks were prepared as described previously: herpes simplex virus type 1 (HSV-1) (strain KOS), HSV-2 (strain G) (De Clercq et a/., 1980), thymidine kinase-deficient (TK-) HSV-1 (strain VMW-1837) (Vinckier et ei: 1987) (Kawana et a/., 1987) ; human immunodeficiency virus type 1 (HIV-1) (strain HTLV-lIIsiLAI) (Popovic et 8/.; -1984) , HIV-2 (strain LAV-2 RO D ) (Clavel et ei., 1986) 
Antiviral activity assays
For HSV; W, VSV, Coxsackie, polio, parainfluenza-3, Sindbis, Semliki forest, Junin, Tacaribe and reovirus, the assay procedures have been described previously (De Clercq et a/.,1975 , 1980 Andrei and De Clercq, 1990) . Confluent (Vero, HeLa or PRI<) cell cultures in 96-well microtitre trays were exposed to 100 CCID so (1 CCID so being the infective dose for 50% of the cell cultures) of virus per well in the presence of varying concentrations of the test compounds diluted in Eagle's minimum essential medium (MEM) supplemented with 3% FCS, 2mM l-glutamine and 0.1% sodium bicarbonate. The cells were further incubated at 3rC until virus-induced cytopathicity was completed in the control (virus-infected untreated) cell cultures. The inhibitory effects of the test compounds on HIV-1 and HIV-2 replication were monitored by the inhibition of virusinduced cytopathicity in MT-4 cells. Briefly, MT-4 cells were suspended at 3 x 10 5 cells per ml and infected with HIV-1 or HIV-2 at 100 CCID 5 D per ml. Immediately after infection, 100 ILlof the cell suspension were brought into each well of a flat-bottomed microtitre tray containing various concentrations of the test compounds. After 5 days incubation at 3rC, the number of viable cells was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTl) method, as previously described (Pauwels et a/., 1988) .
For influenza virus and RSV, confluent cell cultures (MOCK and Hel,a, respectively) in microtitre trays were inoculated with 20 CCID5D ofthe virus per well. The cells were further incubated in the presence of various concentrations of the test compounds and monitored for virus-induced cytopathicity as described previously (Kawana et a/., 1987; Shigeta et a/., 1988) .
For the anti-CMV assays, human embryonic lung (HEl) fibroblasts were infected with 100 p.f.u. of virusr.Compounds and virus were added at the same time and the cells were further incubated at 3rC in MEM supplemented with 2% FCS, 2mM l-glutamine and 0.02% sodium bicarbonate. Virus plaque formation was monitored as described previously (Snoeck et a/., 1988) .
Virus-induced cytopathicity was recorded at 1 or 2 days post infection for VSV; at 2 days for Coxsackie virus, Semliki forest virus and poliovirus; at 2 or 3 days for HSV-1(KOS),HSV-2(G),TK-HSV-1(VMW-1837),Wand Sindbis virus; at 3 days for influenza A and B virus and respiratory syncytial virus; at 4 to 5 days for parainfluenza virus; at 5 days for Junin virus, Tacaribe virus, HIV-1 and HIV-2; and at 6 to 7 days for CMV and reovirus.
Giant cell syncytium formation
MOLT-4(clone 8) cells (1 x 10 6 cells mr') were cultured with an equal number of persistently HIV-1-or HIV-2-infected HUT-78 cells in microtitre tray wells containing various concentrations of the test compounds. After a 24-h cocultivation period, the number of giant cells (syncytia) was recorded microscopically, as described previously (Baba et a/., 1990b) .
Virus adsorption assay
The inhibitory effect of the test compounds on virus adsorption was measured by an indirect immunofluorescence-laser flow cytofluorographic method which had been specifically designed for this purpose (Schols et el., 1989a) . Briefly, MT-4 cells were exposed to HIV-1 virions, which had been concentrated from the supernatant of persistently HIV-1-infected HUT-78 cells in the presence or absence of the test compounds. The compounds were added 10-20s before the virus was added. The cells were processed for indirect immunofluorescence using a polyclonal antibody to HIVe1, and analysed for cell-bound HIV-1 virions by laser flow cytofluorography.
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Glycoprotein gp 120 immunofluorescence assay Normal HUT-78 and HIV-1-infected HUT-78 (HUT-78/HIV-1) cells were grown in RPMI 1640 supplemented with 10% heat-inactivated fetal calf serum (FCS),100 IU rnr' of penicillin G, and 20 ILg mr ' of gentamicin. HUT-78/HIV-1 cells (200000 cells) in 100ILIof RPM) with 10% FCS were washed twice in RPMI with 10% FCS, incubated with the compounds at various concentrations at 20°C for 15-20 min in RPMI with 10% FCS, washed twice with RPMI to remove residual compound, stained with anti-gp120 mAb (9284, DuPont de Nemours, Brussels, Belgium) for 45 min at 3rC, washed twice in PBS, incubated with FITC-conjugated F(ab'b fragments of rabbit anti-mouse immunoglobulin antibody [RaM-IgG-F(ab'kFITC] (Prosan, Ghent, Belgium) for 45-50 min at 3rC, washed twice in PBS, resuspended in 0.5 ml of 0.5% paraformaldehyde in PBS, and analysed by flow cytometry, as described previously (Schols et el., 1990b) . The threshold of positivity for green fluorescence intensity was arbitrarily established on the basis of (i) control uninfected HUT-78 cells incubated with anti-gp120 mAb and RaM-lgG-F(ab'b-FITC or (ii) HIV-1-infected HUT-78 cells incubated solely with RaM-lgG-F(ab'kFITC.
Anticoagulant activity assay
Anticoagulant activity of PAPS and dextran sulphate were assessed by the standard methods for measuring the activated partial thromboplastin time (APTl) of plasma containing the compounds at various concentrations, as described previously (Vermylen and Verstraete, 1960; Refsum et a/., 1978) .
Pharmacokinetics
Serum concentrations of the compounds, following intravenous administration to rabbits, were determined by an anti-HIV-2 bioassay developed previously (Witvrouw et el., 1990) . The rabbits received an intravenous injection (in the ear vein) of PAPS at a dose of 0.1 g kg-1 • At differenttimes after injection, blood was collected from the rabbit's other ear and kept at 4°C overnight, after which the serum was collected. The serum samples were stored at -20°C until assayed. The compound concentrations in the serum were determined by measuring the inhibitory effects of the serum samples on HIV-2-induced cytopathicity in MT-4 cells.
Interferon induction
PAPS and dextran sulphate were dissolved in phosphate-buffered saline (PBS) and injected intraperitoneally (l.p.) in adult NMRI (25g) mice at a dose of 10, 40, or 120mg kg-1 (5 mice per group). The mice were bled at 8 and 24h after administration of the compounds. Interferon determinations were carried out with the plaque inhibition technique (DeClercq and De Somer, 1968) in murine L-929 fibroblasts using VSV as the challenge virus. Five-fold dilutions of the mouse serum were incubated at 37°C on l-929 fibroblasts in 60-mm tissue culture dishes. After 1 day, an optimal infectious dose of VSV was added to each plate, and two days later virus-induced plaques were counted after neutral red staining. The assay was calibrated with standard mouse a/13 interferon.
Standard mouse al[3 IFN was prepared in L-929 cells induced with Newcastle disease virus, concentrated and partially purified by fractional precipitation with ammonium sulphate (Heremans et al., 1978) . To characterize the type of IFN, neutralization assays were performed, as described by Hoss et al. (1989) . The serum samples (from mice treated with PAPS or dextran sulphate) were incubated with polyclonal goat anti-mouse al[3 IFN antibody (kindly provided by Dr H. Heremans, Rega Institute for Medical Research) for 4 h at 37"C. The antibody concentration used was optimal for neutralization of mouse al[3 IFN. ResiduallFN activity in the samples was assayed in L-929 cells, as described above.
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